LILLE, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces the absence of a safety risk due to pharmacokinetic drug-drug interaction when GFT505 is co-administered with a statin (GFT505-1095 clinical study). These results prepare the launch of Phase IIb and Phase III trials in patients already treated with a statin (on-top of statin trials). Furthermore, GENFIT is now evaluating the opportunity to develop a combination therapy associating GFT505 with a generic statin in the same pill.
